Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab and Nivolumab with SBRT and Surgery for Hepatocellular Cancer
NCT07075120Phase 1Recruiting
- Sponsor
- University of Hawaiʻi
- Start
- Apr 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ipilimumab and nivolumab in hepatocellular carcinoma (HCC), sponsored by University of Hawaiʻi. Primary endpoints: Feasibility of Treatment Regimen at 12 months and R0 Resection Rate at 12 weeks. Started Apr 2026; status: recruiting.
02
Drugs
ipilimumabnivolumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07075120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07075120.